KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Shares Outstanding (Weighted Average) (2018 - 2025)

Esperion Therapeutics' Shares Outstanding (Weighted Average) history spans 8 years, with the latest figure at $207.9 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) changed N/A year-over-year to $207.9 million; the TTM value through Dec 2025 reached $207.9 million, changed N/A, while the annual FY2025 figure was $207.9 million, N/A changed from the prior year.
  • Shares Outstanding (Weighted Average) reached $207.9 million in Q4 2025 per ESPR's latest filing, up from $26.1 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $207.9 million in Q4 2025 to a low of $26.0 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $77.0 million, with a median of $37.0 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding (Weighted Average): skyrocketed 177.94% in 2024, then plummeted 86.63% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $28.9 million in 2021, then surged by 129.76% to $66.4 million in 2022, then skyrocketed by 55.26% to $103.1 million in 2023, then surged by 89.06% to $194.9 million in 2024, then increased by 6.64% to $207.9 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Shares Outstanding (Weighted Average) are $207.9 million (Q4 2025), $26.1 million (Q3 2025), and $26.1 million (Q2 2025).